Paid-members only Molecular Testing At-home testing companies were put on notice with FDA's most recent warning letter to Molecular Testing Labs
Paid-members only Start-Upomics Tempus' good very bad week included a $410m IPO, a lawsuit and a ~$20 swing in their post-IPO stock price
